Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 26 h ago

KAZIA THERAPEUTICS LTD: ADAR1 Capital Management, LLC discloses a stake of more than 5% (Schedule 13G)

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 17 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

ADAR1 Capital Management, LLC has disclosed a stake exceeding 5% in Kazia Therapeutics Ltd via a Schedule 13G filing with the SEC (accession 0001104659-26-128727). The exact share count and percentage were not specified in the headline disclosure. The move signals new institutional interest in the clinical-stage oncology company, whose shares are closely tied to pipeline developments. Investors will watch for further detail on the position's size and intent, and for any subsequent 13G amendments or 13D filings that would indicate activist involvement.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Kazia Therapeutics Ltd, ADAR1 Capital Management, LLC